Shekher Bose: Asundexian’s Targeted Factor XIa Inhibition May Transform Secondary Stroke Prevention Strategies
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence’s post on LinkedIn, adding:
”Asundexian’s targeted Factor XIa inhibition offers potent antithrombotic protection with a differentiated safety profile (minimal impact on hemostasis), potentially transforming care for millions worldwide and could pave the way for broader, safer secondary stroke prevention strategies—if approved.”
Quoting Beyondsight Intelligence‘s post:
”Bayer’s Asundexian Cuts Stroke Risk by 26%, No increase in major bleeding in Phase 3
Bayer reported positive topline results from the Phase 3 OCEANIC-STROKE trial evaluating asundexian (50 mg), an investigational once-daily oral Factor XIa inhibitor.
Key Highlights:
• 26% reduction in recurrent stroke risk vs placebo
• Studied in patients with prior non-cardioembolic ischemic stroke or high-risk TIA
• Added on top of standard antiplatelet therapy
• No increase in ISTH major bleeding vs placebo
• Designed for effective thrombosis prevention with a wider safety margin
Why It Matters:
• Current antithrombotics often require a trade-off between efficacy and bleeding risk
• Factor XI inhibition is emerging as a next-generation anticoagulation strategy
• Could enable safer long-term secondary stroke prevention
Key Takeaway:
Asundexian’s Phase 3 results suggest meaningful stroke risk reduction without the usual bleeding penalty—potentially reshaping the future of antithrombotic therapy.
Follow our page for more such updates.
News Source Demonstrated a Substantial Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack With No Increase in ISTH Major Bleeding Versus Placebo”
Stay updated with Hemostasis Today.
-
Jun 27, 2026, 01:31Alessio De Rose: Addressing Micronutrient Deficiencies in the Era of GLP-1 Receptor Agonists
-
Jun 27, 2026, 01:21Michelle Sámano Sánchez: Exploring Vitamin C as an Adjunct Therapy for Anemia in Hemodialysis
-
Jun 27, 2026, 01:08Ana Raquel Gotine: The First Pragmatic Clinical Trial on MNPs and Childhood Anemia in Mozambique
-
Jun 27, 2026, 00:56Sherif Badawy: Reflecting on My Time with ASH CRTI
-
Jun 27, 2026, 00:48Zain Khalpey: Why High quality CPR is Only Part of Successful Cardiac Arrest Management
-
Jun 26, 2026, 22:31Wendy Dusenbury: The New Issue of the Stroke Clinician is Now Live
-
Jun 26, 2026, 20:42Ed Watson: When It Happens to You, Stroke Becomes Personal, Immediate, and Life-Changing
-
Jun 26, 2026, 19:45Nathan Connell: Transforming Surgical Care with Tranexamic Acid
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?